
Supernus, Inc.
SUPN
Updated: 05/11/2026, 09:20:37
No historical data available
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.
No summaries found.
- Share price
- $28.21
- Market cap
- $1.64B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jack A. Khattar
- Employees
- 778
- IPO date
- 30/04/2012
- Beta
- 0.5206186
- Last dividend
- $0.00
- Day range
- $26.74 – $28.99
- 52-week range
- $26.74 – $44.31
- 1-day performance
- 0.21%
- 1-year performance
- 5.50%
- Current drawdown (1Y)
- -36.33%
- CIK
- 0001356576
- CUSIP
- 45579U109
- ISIN
- US45579U1097
- Created
- 07/12/2025, 14:26:05
- Last update
- 05/11/2026, 09:20:37
Track Supernus, Inc. with an AI analyst
See which prediction-market events move SUPN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Supernus Pharmaceuticals to Participate in June Investor Conferences
GlobeNewsWire • STOCK • 27/05/2026, 18:30:00
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 03:10:44
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
GlobeNewsWire • STOCK • 06/05/2026, 19:00:00
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 00:21:16
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research • STOCK • 05/05/2026, 22:01:19
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 11/03/2026, 16:52:18
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 25/02/2026, 05:27:57
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research • STOCK • 25/02/2026, 00:30:18
Supernus Pharmaceuticals to Participate in March Investor Conferences
GlobeNewsWire • STOCK • 23/02/2026, 19:15:00
Lunai Bioworks, Inc. Issues Letter to Shareholders
PRNewsWire • STOCK • 09/02/2026, 12:14:00
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Seeking Alpha • STOCK • 01/02/2026, 08:59:59